Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2012 Oct 4;131(2):461–467.e5. doi: 10.1016/j.jaci.2012.07.055

Figure 1.

Figure 1

Flow diagram of subject follow-up with transition to different stages. Note: all subjects who were withdrawn due to termination of the study by the sponsor were eligible to continue receiving mepolizumab on a compassionate use protocol.

HHS Vulnerability Disclosure